Dr Raab on Teclistamab-Based Regimens in Newly Diagnosed Multiple Myeloma

“The response rates not only deepened over time but reached nearly 100% across all cohorts. The first cohort had a complete response [CR] rate of 100%, the second cohort had a CR rate of 95%, and the third [cohort] was a bit lower at 73.7%.”

Marc S. Raab, MD, a professor of medicine and the clinical director of the Heidelberg Myeloma Center in the Department of Medicine V at Heidelberg University Hospital discussed findings from a post-induction outcomes and minimal residual disease (MRD) analysis of the phase 2 MajesTEC-5trial (NCT05695508) of teclistamab-cqyv (Tecayli) for the treatment of patients with newly diagnosed multiple myeloma.

Findings presented during the 22nd Annual International Myeloma Society (IMS) Meeting and Exposition, showed that patients who received teclistamab every week in combination with daratumumab and lenalidomide (Tec-DR; arm A; n = 10), Tec-DR with teclistamab every 4 weeks (arm A1; n = 20) or teclistamab plus daratumumab, bortezomib, and lenalidomide (Tec-DVR; arm B; n = 19) all achieved overall response rates of 100%, Raab began. Patients in arm A achieved a complete response (CR) or better rate of 100%, and those in arms A1 and B experienced CR or better rates of 95% and 73.7%, respectively, he added.

The MRD negativity rates across these arms were also promising, Raab noted. At a threshold of 10-5, all patients in arms A (n = 10), A1 (n = 19), and B (n = 17) with available samples reached MRD negativity at the end of both cycle 3, he highlighted. These findings were confirmed at the end of cycle 6 by flow cytometry, he said. Overall, the cumulative MRD negativity rate across all arms (n = 49) by the end of induction in the efficacy analysis set was 98.0%.